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LETTERS TO THE EDITOR 
Differential Effect of Thrombolytic Therapy 
Ritchie et al. (I) recently examined limitation of infarct size, 
estimated by thallium-201 tomography, after thrombolytic therapy 
with intravenous streptokinase in a subgroup of 207 patients 
participating in the Western Washington intravenous streptokinase 
trial. The authors report that the greatest benefit of thrombolytic 
therapy occurred in patients with anterior infarction who were 
treated within 3 h after the onset of symptoms. There was little 
benefit in patients with inferior infarction or in patients with ante- 
rior infarction admitted after 3 h. These findings are in agreement 
with the subgroup analysis of the trial on intracoronary streptoki- 
nase, conducted by the Netherlands Interuniversity Cardiology 
Institute (2). In that analysis the beneficial effects of thrombolytic 
therapy on infarct size (estimated from myocardial enzyme release), 
global left ventricular function and survival were related to two 
factors: the delay between onset of symptoms and therapy and 
the extent of myocardial ischemia estimated from the total amount 
of ST segment elevation in the admission electrocardiogram 
(ECG). When the admission ECG was taken into account, infarct 
location was not related to the effect of thrombolytic therapy, 
Generally, anterior infarctions are larger than inferior wall infarc- 
tions. The effect of thrombolytic therapy appeared to be related to 
the size of the ischemic area and not as much to the site of the 
infarction. It would be of great interest to know whether similar 
effects were observed in the Western Washington intravenous 
streptokinase trial. 
It is now evident that thrombolytic therapy is useful in certain 
subgroups of patients with acute myocardial infarction and certain- 
ly not in all types of infarction. More studies, such as the report 
by Ritchie et al. (I), are needed to further delineate those patients 
who do and those who do not benefit from thrombolytic therapy, 
The use of threshold values such as anterior infarction within 
3 h after the onset of symptoms may appeal to clinicians because 
of their simplicity. However, such selection criteria for throm- 
bolytic therapy in our opinion do not reflect the more compli- 
cated clinical reality. It may be more appropriate to apply a set 
of inclusion criteria combining the delay between onset of 
symptoms and the total amount of ST segment elevation. For 
example, from the data in the trial by the Netherlands Interuniver- 
sity Cardiology Institute a so-called rule of four was developed. 
According to that rule, thrombolytic therapy is warranted in patients 
admitted within 1 h after the onset of symptoms who exhibit a sum 
of ST segment elevation in all 12 leads of 0.4 mV. In patients 
admitted between I and 2 h, the ST segment elevation should be 8 
mm, 0.8 mV; between 2 and 3 h, 0.12 mV and between 3 and 4 h, 
0+16 mV. 
MAARTEN L. SIMOONS, MD, FACC 
Thoraxcenter, on behayof the 
Study Group of The Netherlands 
Inreruniversiry Cardiology lnstirure 
Rotter&ii;, T/w Nrrherlunlls 
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Reply 
We did not collect ST segment data and cannot comment on their 
utility, and they have not been repotted in most other trials. We thus 
cannot ascertain from our data whether infarct size alone, or 
possibly other contributing coronary anatomic/physiologic features, 
can explain the differences between the anterior and inferior infarc- 
tion groups. We agree that further information is needed. 
JAMES L. RITCHIE, MD, FACC 
J. WARD KENNEDY, MD, FACC 
University of Washington 
Seattle, Washington 98108 
Dipyridamole-Induced ST Segment 
Depression by CollateraE Steal? 
Chambers and Brown (I) propose as determinants of dipyridarnole- 
induced ST segment depression an increased rate-pressure product 
and the presence of “good” collateral vessels at coronary angiog- 
raphy. They found that among patients with (visually estimated!) 
high grade stenosis (295% luminal diameter narrowing), dipyri- 
damole-induced ST segment depression was more common in 
patients with than in patients without good collateral vessels. The 
authors suggest that the collateral vessels are therefore responsible 
for the observed ST segment depression. In my view, ST segment 
depression afIer dipyrldamole infusion in the presence of collateral 
vessels indicates that the stenosis at angiography is also physiolog- 
ically signhlcant. Therefore, the relation between collateral vessels 
and ST segment depression must be an indirect one. Furthermore, it 
is difficult tojudge the functional significance of collaleral vessels by 
the coronary arteriogram and their appearance may vary consider- 
ably in time and among various injections of contrast medium in the 
same patient. 
For their methods of quantitative analysis, the authors refer to 
the excellent article of Wackers et al. (2), which deals with exercise 
thallium-201 testing. Did the authors use test-specific normal profiles 
for dipyridamole thallium-201 testing derived from subjects with low 
likelihood of coronary artery disease? 
Referencea 
1. Chambers CE, Ltmwn KA. Dipytidamole-induced ST segment depression during 
thallium-201 imaging in patients with connary attcty disease: aagiographic aad hem* 
Gyusnic: delcm~insnb. J Am Cull CuJiui 19SS,i2.37-lI. 
619Sil by the American College of Cardiology 03’?5-1097/88/$3.5a 
JACC Vol. 12, No. 5 
November X988:1392 
2. Wacken FJT. Fc~~crman RC. Mat~era 1. et al. Quantitative planar thallium-MI stress 
xi&mphy: a critical cvaluaGon of the method. &mitt Nuct Med 1985;15:444. 
GERRIT J. LAARMAN, MD 
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Laarman is correct in pointing out the limitations of angiographic 
assessment of collateral vessels. Although in the text we ack;A:wt- 
edged ihat our observations do not prove causation, we basrc! our 
con&ion that dipyridamole-induced ischemia is related to collat- 
eral vessels on the finding that there was a significant correlation 
between the presence of good angiographic collateral vessels and 
the development of dipyridamole-induced ST segment depression in 
the total population as a whole. We feel that such a relation is best 
explained by the facilitation of coronary steal by collateral vessels as 
explained in the text, The subgroup of patients with high grade 
stenosis (>95% huninal diameter narrowing) was analyzed because 
of our concern that the presence of good angiographic collateral tic .* 
was simply a marker of severe disease. However, as we reported. 
even in this subgroup of patients there was a significant relation 
between dipyridamok-induced ST segment depression and the 
presence of good angimphic collateral Row. Certainly the mere 
presence of collateral vessels does not alone define whether a lesion 
is “physiologically significant ” 
Laarman correctly points but that the quantitative thallium-201 
analysis used circumferential profiles that were estabfished for 
exercise thallium-201 imaging. We did not use dipyridamole thal- 
lhun-2OLspecfi normal profiles for our study. vowever, each 
study was interpreted using the quantitative program in the context 
of visual, qualitative inspecdon of images for the presence of 
abnormalities. 
KENNETH A. BROWN, MD, FACC 
Assistant Professor of Medicine 
iiniversity of Vermont College of Medicine 
Burlington. Vermont 05405 
for Death 
The article by Kirklin et al. (1) is intriguing. it is an expansion of 
their earlier experience in cardiac transplantation that is reported in 
the textbook by Kirklin.ar.:G Barrett-Boyes (2). As usual, detailed 
statistical analysis accompanies their data and conclusions. How- 
ever, there is a paucity of relevant descriptive information, which 
makes their conclusions difficult to accept. A further elaboration on 
the three preoperative variables ihat they have identified as signifi- 
cant risk factors for death subsequent to transplantation would be 
enlightening. 
1. Ii& p&onary vaseuku resUnce. This is described in the 
usual manner. The known caution that must be exercised when 
performing cardiac transplantation in patients with severe or fixed 
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pulmonary hypertension makes the use of heterotopic transplanta- 
tion understandable in at least three of their patients. It would have 
been interesting to see the hemodynamic differences in more detail 
from those receiving an orthotopic transp&nt. Figure 3 in their 
art&e seems to be mislabeled. Shouldn’t it read “Actuarial Survival 
in 51 Transplants”? Because 12 of the 63 patients (1%) did not have 
a pulmonary vascular resistance to include in their multivariate 
analysis, how has this really affected the results? What statistical 
assumptions or corrections were made to make complete data on 5 t 
patients predict the statistical significance of the incompicte data in 
63 patients? 
2. Black race. Because the number of black versus white patients 
is not given, the statistical significance of this unalterable variable 
has isolated meaning. One can only assume that black patients made 
up a substantial portion of their stu?] population. This institution 
has previously had a very small percentage of black patients 
included in their most common cardiac surgical series (3). If blacks 
comprise d significant percentage of their patients undergoing ttans- 
plan,ation either early or late in their surgicat experience, is there 
some clinical significance that they are overlooking? The definition 
and significance of race as a biologic profire are questionable at best 
(4). and these authors have nol provided any of the other more 
meaningful demographic information that could bring us closer to 
the truth of the matter. Table 2 in their article equates race with 
demography-a somewhat narrow definition compared with those in 
medical and lay dictionaries. 
3. Morph&gy ofcar&amyvpathy. The present study has a high 
percentage (67%) of patients with idiopathic cardiomyopathy. Be- 
cause statistical anatysis indicates that their best survival rates 
occurred in white patients with ischemic heart disease, the descrip 
tion of the patients with cardiomyopathy may have importance. It 
seems possible that a significant portion of them may have been 
black, or had hypertension with its sequeIae or had a past medical 
history or other findings with some relation to their myopathic state 
or eventual outcome. Excised hearts must have had some histo- 
pathologic findings. 
The operative mortality and early and late survival of this 
surgical series is only moderately at variance with the more recent 
mortality figures (80 to 90% at I year, SO% at 5 years) that are quoted 
by many institutions (5,6) and planning boards, some of which have 
used these improved survival figures of the cyclosporine era as a 
rationale for increasing the availability of cardiac transplant serv- 
ices. Tl-ere is no reason to expect the researchers from Alabama to 
have avoided perhaps more difficult cases with an uncertain mortal- 
ity. Some of their candidates clearly represented a formidable 
intraoperative challenge. Their overall results are important in 
confirming the value of cyclosporine. but a better description of 
their patient population would help those of us who see a significant 
number of black patients. Other centers do not seem to have 
detected race as a relevant variable in their cardiac transplant resulrs 
regardless of the presence of idiopathic cardiomegaly (7) or in 
reviewing cardiac transplantation issues in general. The cardiovas- 
cular morbidity and mortality of black citizens are well documented 
(8) and usual or unusual risk factors may adversely tiect their 
surgical and medical outcomes independent of race. The Discussion 
section of the article does not examine the possible pathophysiologic 
factors that might be correlated with race but instead substitutes 
“psychosocial factors” and patient compliance in one sentence. If 
